PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 12:02 AM ET

Sponsor Check › Person

Corey Goodman

Related person on Form D filings · address states as listed: CA, TX, L2, MA, PA · listed Jul 16, 2009 → Jul 12, 2024

21issuers
63Form D filings
2009–2024years listed

Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet

Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.

Key records

The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.

1. Lawsuits

None found in sources searched.

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

Not yet searched.

Search queued. Results are added automatically; check back later or follow this page to be notified.

3. Bankruptcies

None found in sources searched.

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons are made for sponsors and sponsor groups, not individual people.

5. Money to insiders and sales commissions

4 of 38 offerings report sales commissions totalling $8,132,738; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

SourceOffering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell it
EDGAR ↗Nov 1, 2024 D
File 021-528494
$0$0$0 (est.)None listed on this filing
EDGAR ↗Jul 12, 2024 D
File 021-518549
$0$0$0None listed on this filing
EDGAR ↗Feb 9, 2024 D
File 021-504871
$0$0$0None listed on this filing
EDGAR ↗Dec 22, 2023 D
File 021-500662
$0$0$0None listed on this filing
EDGAR ↗Jul 21, 2023 D
File 021-487531
$0$0$0None listed on this filing
EDGAR ↗Mar 20, 2023 D
File 021-476362
$0$0$0None listed on this filing
EDGAR ↗Dec 2, 2022 D
File 021-466472
$0$0$0None listed on this filing
EDGAR ↗Jun 21, 2022 D/A
File 021-448741
$0$0$0None listed on this filing
EDGAR ↗Sep 24, 2021 D
File 021-414543
$0$0$0None listed on this filing
EDGAR ↗Jul 22, 2021 D/A
File 021-371827
$0$0$0None listed on this filing
EDGAR ↗May 14, 2021 D
File 021-399537
$2,435,860 (est.)$0$0BA Securities LLC BrokerCheck CRD 153489 ↗
Far Hills Group, LLC BrokerCheck CRD 32243 ↗
EDGAR ↗Jun 18, 2020 D
File 021-369265
$0$0$0None listed on this filing
EDGAR ↗Apr 24, 2020 D/A
File 021-278526
$0$0$0None listed on this filing
EDGAR ↗Apr 24, 2020 D
File 021-365710
$0$0$0None listed on this filing
EDGAR ↗Mar 26, 2020 D/A
File 021-314554
$0 (est.)$0 (est.)$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
Far Hills Group LLC BrokerCheck CRD 32243 ↗
BA Securities, LLC BrokerCheck CRD 153489 ↗
EDGAR ↗Jan 28, 2020 D/A
File 021-347004
$0$0$0None listed on this filing
EDGAR ↗Apr 1, 2019 D/A
File 021-327684
$0$0$0None listed on this filing
EDGAR ↗Jun 16, 2017 D
File 021-288881
$0$0$0None listed on this filing
EDGAR ↗Mar 2, 2017 D/A
File 021-236281
$0$0$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
None listed on this filing
EDGAR ↗Feb 16, 2017 D/A
File 021-246410
$0$0$0None listed on this filing
EDGAR ↗Oct 11, 2016 D/A
File 021-146407
$3,138,096 (est.)$0 (est.)$0 (est.)
Issuer's investment manager and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a master fund.
Far Hills Group LLC BrokerCheck CRD 32243 ↗
Direct Access Partners, LLC BrokerCheck CRD 120950 ↗
EDGAR ↗Oct 11, 2016 D/A
File 021-146405
$1,771,282 (est.)$0 (est.)$0 (est.)
Issuer's managing member and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a feeder fund.
Far Hills Group LLC BrokerCheck CRD 32243 ↗
EDGAR ↗Dec 30, 2015 D
File 021-254171
$0$0$0None listed on this filing
EDGAR ↗May 21, 2015 D
File 021-240360
$0$0$0None listed on this filing
EDGAR ↗May 1, 2015 D
File 021-239002
$0$0$0None listed on this filing
EDGAR ↗Oct 3, 2014 D
File 021-225788
$0$0$0None listed on this filing
EDGAR ↗Oct 29, 2013 D/A
File 021-150376
$0$0$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
None listed on this filing
EDGAR ↗Dec 28, 2012 D
File 021-189143
$0$0$0None listed on this filing
EDGAR ↗Dec 28, 2012 D
File 021-189144
$0$0$0None listed on this filing
EDGAR ↗Dec 12, 2012 D
File 021-188236
$0$0$0None listed on this filing
EDGAR ↗Nov 2, 2012 D
File 021-186414
$787,500 (est.)$0$0Ferghana Securities, Inc. BrokerCheck CRD 43430 ↗
EDGAR ↗Jan 30, 2012 D
File 021-172591
$0$0$0None listed on this filing
EDGAR ↗Aug 23, 2011 D
File 021-164825
$0$0$0None listed on this filing
EDGAR ↗Aug 9, 2011 D
File 021-164097
$0$0$0None listed on this filing
EDGAR ↗Jul 26, 2011 D/A
File 021-152195
$0$0$0None listed on this filing
EDGAR ↗Nov 9, 2010 D/A
File 021-144981
$0$0$0None listed on this filing
EDGAR ↗Aug 20, 2009 D/A
File 021-88136
$0$0$0
Funds to be used for working capital.
None listed on this filing
EDGAR ↗Jul 16, 2009 D
File 021-132857
$0$0$0None listed on this filing

As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Appears on these filings

SourceIssuerRoleFiledFormOfferingSoldInvestorsMin. investment
EDGAR ↗Axonis Therapeutics, Inc.DirectorNov 1, 2024D$115,000,000
similar: $2,000,000–$19,999,994
$46,000,00019
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund V, L.P.
group: Venbio
Executive OfficerJul 12, 2024DIndefinite
similar: $155,000–$5,250,000
$504,700,000162
similar: 4–27
$62,500
similar: $1,000–$100,000
EDGAR ↗Attralus, Inc.DirectorFeb 9, 2024D$55,999,931
similar: $2,000,000–$19,999,994
$55,999,93112
similar: 2–16
$24,405
similar: $10,000–$50,000
EDGAR ↗INSAMO INC.DirectorDec 22, 2023D$2,300,000
similar: $2,000,000–$19,999,994
$2,300,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗NFlection Therapeutics, Inc.DirectorJul 21, 2023D$4,000,000
similar: $2,000,000–$19,999,994
$4,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗INSAMO INC.DirectorMar 20, 2023D$10,000,000
similar: $2,000,000–$19,999,994
$9,524,9984
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗FOG PHARMACEUTICALS, INC.DirectorDec 2, 2022D$177,999,922
similar: $1,694,259–$16,000,000
$177,999,92224
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗NFlection Therapeutics, Inc.DirectorJun 21, 2022D/A$30,000,000
similar: $2,000,000–$19,999,994
$20,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗NFlection Therapeutics, Inc.DirectorJun 10, 2022D$20,000,000
similar: $2,000,000–$19,999,994
$10,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Attralus, Inc.DirectorSep 24, 2021D$116,599,889
similar: $2,000,000–$19,999,994
$116,599,88922
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Tallac Therapeutics, Inc.DirectorJul 22, 2021D/A$61,616,192
similar: $829,831–$9,999,998
$61,616,19212
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗venBio Global Strategic Fund IV, L.P.
group: Venbio
Executive OfficerMay 14, 2021D$550,000,000
similar: $155,000–$5,250,000
$549,936,000147
similar: 4–27
$125,000
similar: $1,000–$100,000
EDGAR ↗Tallac Therapeutics, Inc.DirectorJul 27, 2020D$40,350,000
similar: $829,831–$9,999,998
$21,175,00010
similar: 2–15
No minimum reported
similar: $10,000–$54,310
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorJun 18, 2020D$100,083,274
similar: $2,000,000–$19,999,994
$85,083,28017
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗NFlection Therapeutics, Inc.DirectorApr 24, 2020D/A$24,000,000
similar: $2,000,000–$19,999,994
$20,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorApr 24, 2020D$10,000,000
similar: $2,000,000–$19,999,994
$10,000,0004
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund III, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Mar 26, 2020D/A$386,055,000
similar: $155,000–$5,250,000
$386,055,000100
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorJan 28, 2020D/A$15,999,999
similar: $2,000,000–$19,999,994
$15,999,9994
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorAug 20, 2019D$15,999,999
similar: $2,000,000–$19,999,994
$7,999,9964
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorApr 1, 2019D/A$21,999,995
similar: $2,000,000–$19,999,994
$21,999,9954
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund III, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Mar 26, 2019D/A$350,000,000
similar: $155,000–$5,250,000
$118,000,0008
similar: 4–27
$5,000,000
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorDec 12, 2018D$21,999,995
similar: $2,000,000–$19,999,994
$10,999,9984
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund III, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Jun 13, 2018D$350,000,000
similar: $155,000–$5,250,000
$00
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorJun 16, 2017D$27,000,000
similar: $2,000,000–$19,999,994
$27,000,0003
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund II L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Mar 2, 2017D/A$337,000,000
similar: $155,000–$5,250,000
$337,000,00031
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorFeb 16, 2017D/A$25,000,000
similar: $2,000,000–$19,999,994
$25,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗NFlection Therapeutics, Inc.DirectorJan 17, 2017D$14,000,000
similar: $2,000,000–$19,999,994
$1,400,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Avoro Life Sciences Offshore Fund Ltd.
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 11, 2016D/AIndefinite
similar: $155,000–$5,250,000
$249,289,00096
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Avoro Life Sciences Fund LLC
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 11, 2016D/AIndefinite
similar: $155,000–$5,250,000
$412,916,742108
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorJun 30, 2016D/A$20,000,000
similar: $2,000,000–$19,999,994
$20,000,0002
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund II L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Mar 18, 2016D/A$303,000,000
similar: $155,000–$5,250,000
$288,000,00022
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Solstice Biologics LLC
group: Venbio
Executive Officer, Director, Promoter
Mr. Goodman is the President, Chief Executive Officer and a member of the Board of Managers of the Issuer.
Dec 30, 2015D$4,000,000
similar: $1,694,259–$16,000,000
$4,000,0002
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Avoro Life Sciences Offshore Fund Ltd.
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 9, 2015D/AIndefinite
similar: $155,000–$5,250,000
$178,486,50082
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Avoro Life Sciences Fund LLC
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 9, 2015D/AIndefinite
similar: $155,000–$5,250,000
$292,582,52996
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Checkmate Pharmaceuticals, Inc.DirectorAug 25, 2015D$20,030,000
similar: $1,694,259–$16,000,000
$10,030,0002
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Alexo Therapeutics LtdDirectorMay 21, 2015D$36,005,425
similar: $2,000,000–$19,999,994
$18,022,50014
similar: 2–16
$37,500
similar: $10,000–$50,000
EDGAR ↗SYNLOGIC, INC.
group: Synlogic
DirectorMay 1, 2015D$45,000,000
similar: $1,694,259–$16,000,000
$41,789,52724
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗venBio Global Strategic Fund II L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Mar 19, 2015D$250,000,000
similar: $155,000–$5,250,000
$00
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Avoro Life Sciences Offshore Fund Ltd.
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 17, 2014D/AIndefinite
similar: $155,000–$5,250,000
$65,840,00051
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Avoro Life Sciences Fund LLC
group: Venbio
Executive Officer
Managing member of venBio Select Advisor LLC.
Oct 17, 2014D/AIndefinite
similar: $155,000–$5,250,000
$123,974,50042
similar: 4–27
$1,000,000
similar: $1,000–$100,000
EDGAR ↗Solstice Biologics LLC
group: Venbio
Executive Officer, Director
Mr. Goodman is President/CEO and Manager of the Issuer.
Oct 3, 2014D$7,500,000
similar: $1,694,259–$16,000,000
$7,500,0002
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗venBio Global Strategic Fund, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Oct 29, 2013D/A$237,000,000
similar: $155,000–$5,250,000
$177,000,0004
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗Solstice Biologics LLC
group: Venbio
Executive Officer, Director
Mr. Goodman is President/CEO and Manager of the Issuer.
Dec 28, 2012D$7,500,000
similar: $1,694,259–$16,000,000
$7,500,0002
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Labrys Biologics, Inc.
group: Venbio
Executive Officer, DirectorDec 28, 2012D$30,999,997
similar: $1,694,259–$16,000,000
$14,588,2345
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗Solstice Biologics LLC
group: Venbio
Executive Officer, Director
Mr. Goodman is President/CEO and Manager of the Issuer.
Dec 12, 2012D$3,000,000
similar: $1,694,259–$16,000,000
$3,000,0001
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗SYNLOGIC, INC.
group: Synlogic
DirectorNov 2, 2012D$34,499,990
similar: $2,000,000–$19,999,994
$17,249,99517
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗venBio Global Strategic Fund, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Oct 31, 2012D/A$177,500,000
similar: $155,000–$5,250,000
$177,000,0004
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorJan 30, 2012D$480,000
similar: $1,694,259–$16,000,000
$480,0005
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗venBio Global Strategic Fund, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Nov 3, 2011D/A$177,500,000
similar: $155,000–$5,250,000
$175,000,0003
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗SYNLOGIC, INC.
group: Synlogic
DirectorAug 23, 2011D$1,500,000
similar: $2,000,000–$19,999,994
$1,500,0009
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗Second Genome, Inc.DirectorAug 9, 2011D$4,999,999
similar: $2,000,000–$19,999,994
$4,999,99912
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorJul 26, 2011D/A$13,228,591
similar: $1,694,259–$16,000,000
$9,939,41513
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorMar 10, 2011D/A$6,935,000
similar: $1,694,259–$16,000,000
$6,889,41513
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorDec 20, 2010D$3,585,000
similar: $1,694,259–$16,000,000
$3,585,00013
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗venBio Global Strategic Fund, L.P.
group: Venbio
Director
Director of the General Partner of the Issuer's General Partner
Nov 12, 2010D$175,000,000
similar: $155,000–$5,250,000
$75,000,0001
similar: 4–27
No minimum reported
similar: $1,000–$100,000
EDGAR ↗iPierian, Inc.DirectorNov 9, 2010D/A$28,970,000
similar: $1,694,259–$16,000,000
$28,970,00020
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗iPierian, Inc.DirectorSep 9, 2010D/A$28,470,000
similar: $1,694,259–$16,000,000
$28,470,00019
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗iPierian, Inc.DirectorJul 15, 2010D$25,000,000
similar: $1,694,259–$16,000,000
$22,390,00113
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorAug 20, 2009D/A$15,380,000
similar: $2,000,000–$19,999,994
$15,380,00017
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗iPierian, Inc.DirectorJul 16, 2009D$938,590
similar: $1,694,259–$16,000,000
$938,5904
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗iPierian, Inc.DirectorJul 16, 2009D$11,499,998
similar: $1,694,259–$16,000,000
$6,499,9994
similar: 1–13
No minimum reported
similar: $10,000–$55,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorJul 16, 2009D$15,150,000
similar: $2,000,000–$19,999,994
$15,000,0007
similar: 2–16
No minimum reported
similar: $10,000–$50,000
EDGAR ↗LIMERICK BIOPHARMA INCDirectorJun 5, 2009D$1,500,000
similar: $2,000,000–$19,999,994
$1,500,0005
similar: 2–16
No minimum reported
similar: $10,000–$50,000

Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.

"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pooled Investment Fund / 506(b) (83,801 filings); Pharmaceuticals / 506(b) (800 filings); Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Connections as of Oct 23, 2026, 5:45 PM ET

Listed alongside — 40 names on the same filings (9 management entities, 31 people)

People and management entities the issuers listed as related persons on the same Form D filings as Corey Goodman. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.

  • venBio Select Advisor entity — 6 shared filings (2 issuers) · role as listed: Promoter
  • venBio Global Strategic GP, Ltd. entity — 4 shared filings (1 issuer) · role as listed: Director
  • venBio Global Strategic GP II, Ltd. entity — 3 shared filings (1 issuer) · role as listed: Director
  • venBio Global Strategic GP III, Ltd. entity — 3 shared filings (1 issuer) · role as listed: Director
  • Bradwell Limited entity — 1 shared filing (1 issuer) · role as listed: Executive Officer · also listed on 1 other issuer
  • venBio Global Strategic GP IV, LLC entity — 1 shared filing (1 issuer) · role as listed: Promoter
  • venBio Management Company LLC entity — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • venBio Global Strategic GP V, LLC entity — 1 shared filing (1 issuer) · role as listed: Promoter
  • venBio Partners LLC entity — 1 shared filing (1 issuer) · role as listed: Executive Officer
  • Robert Adelman — 22 shared filings (8 issuers) · roles as listed: Director, Executive Officer · also listed on 5 other issuers
  • Michael Powell — 10 shared filings (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • Paul Brooke — 9 shared filings (4 issuers) · roles as listed: Director, Executive Officer
  • Wendye Robbins — 7 shared filings (1 issuer) · roles as listed: Executive Officer, Director · also listed on 2 other issuers
  • Charles Yon — 7 shared filings (1 issuer) · role as listed: Executive Officer
  • Kurt von Emster — 6 shared filings (3 issuers) · roles as listed: Director, Executive Officer · also listed on 10 other issuers
  • Asha Rajagopal — 6 shared filings (1 issuer) · role as listed: Executive Officer
  • Karen Brennan — 6 shared filings (1 issuer) · role as listed: Executive Officer
  • Beth Seidenberg — 5 shared filings (1 issuer) · role as listed: Director · also listed on 28 other issuers
  • Chad Waite — 5 shared filings (1 issuer) · role as listed: Director · also listed on 11 other issuers
  • Ashley L. Dombkowski — 5 shared filings (1 issuer) · role as listed: Director
  • Ketan Patel — 5 shared filings (1 issuer) · role as listed: Director · also listed on 11 other issuers
  • Chuck Abdalian — 5 shared filings (1 issuer) · role as listed: Executive Officer
  • Aaron Royston — 5 shared filings (3 issuers) · role as listed: Executive Officer · also listed on 6 other issuers
  • David Pezeshki — 5 shared filings (3 issuers) · role as listed: Executive Officer
  • Barry Labinger — 5 shared filings (1 issuer) · roles as listed: Executive Officer, Director
  • Berta Strulovici — 5 shared filings (1 issuer) · role as listed: Executive Officer · also listed on 1 other issuer
  • Richard Gaster — 4 shared filings (3 issuers) · roles as listed: Executive Officer, Director · also listed on 3 other issuers
  • Christopher Powala — 4 shared filings (1 issuer) · roles as listed: Executive Officer, Director · also listed on 2 other issuers
  • Krishna Yeshwant — 4 shared filings (2 issuers) · role as listed: Director · also listed on 8 other issuers
  • Ben Auspitz — 4 shared filings (1 issuer) · role as listed: Director · also listed on 5 other issuers
  • Matthew M Winkler — 4 shared filings (2 issuers) · role as listed: Director · also listed on 1 other issuer
  • Arthur Krieg — 4 shared filings (1 issuer) · roles as listed: Executive Officer, Director
  • Steven Dowdy — 4 shared filings (1 issuer) · role as listed: Director
  • Curt Bradshaw — 4 shared filings (1 issuer) · roles as listed: Director, Executive Officer, Promoter
  • Scott Epstein — 4 shared filings (2 issuers) · role as listed: Executive Officer · also listed on 2 other issuers
  • Behzad Aghazadeh — 4 shared filings (2 issuers) · role as listed: Executive Officer · also listed on 4 other issuers
  • Keith Flaherty — 4 shared filings (1 issuer) · role as listed: Director · also listed on 3 other issuers
  • Alan Fuhrman — 4 shared filings (1 issuer) · role as listed: Director
  • Robert Weisskoff — 3 shared filings (1 issuer) · role as listed: Director · also listed on 17 other issuers
  • Robert Higgins — 3 shared filings (1 issuer) · role as listed: Director · also listed on 10 other issuers

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Export this report as PDF (members · included free during the launch period)

Change history

No corrections have been requested for this page.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Corey Goodman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →